State of New Jersey Common Pension Fund D Reduces Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD)

State of New Jersey Common Pension Fund D reduced its position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 14.3% in the third quarter, HoldingsChannel.com reports. The institutional investor owned 170,264 shares of the biopharmaceutical company’s stock after selling 28,438 shares during the period. State of New Jersey Common Pension Fund D’s holdings in Amicus Therapeutics were worth $1,818,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Old West Investment Management LLC grew its stake in Amicus Therapeutics by 617.2% during the 3rd quarter. Old West Investment Management LLC now owns 340,441 shares of the biopharmaceutical company’s stock valued at $3,636,000 after purchasing an additional 292,976 shares in the last quarter. AlphaCentric Advisors LLC grew its position in shares of Amicus Therapeutics by 1.2% during the third quarter. AlphaCentric Advisors LLC now owns 205,000 shares of the biopharmaceutical company’s stock worth $2,189,000 after buying an additional 2,500 shares in the last quarter. Hazlett Burt & Watson Inc. increased its stake in shares of Amicus Therapeutics by 156.9% in the third quarter. Hazlett Burt & Watson Inc. now owns 2,569 shares of the biopharmaceutical company’s stock worth $28,000 after buying an additional 1,569 shares during the last quarter. Arcadia Investment Management Corp MI acquired a new stake in Amicus Therapeutics in the third quarter valued at $32,000. Finally, Fullcircle Wealth LLC bought a new position in Amicus Therapeutics during the 3rd quarter valued at $136,000.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on FOLD. JPMorgan Chase & Co. boosted their target price on shares of Amicus Therapeutics from $16.00 to $17.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 12th. Bank of America upped their price objective on Amicus Therapeutics from $13.00 to $15.00 and gave the company a “buy” rating in a research note on Thursday, October 17th. Jefferies Financial Group began coverage on Amicus Therapeutics in a research report on Friday, September 6th. They issued a “buy” rating and a $18.00 target price for the company. Guggenheim upped their price target on Amicus Therapeutics from $13.00 to $15.00 and gave the company a “buy” rating in a research report on Thursday, November 7th. Finally, Morgan Stanley decreased their price objective on shares of Amicus Therapeutics from $19.00 to $18.00 and set an “overweight” rating for the company in a report on Friday, October 11th. One investment analyst has rated the stock with a hold rating and nine have given a buy rating to the company. According to MarketBeat, Amicus Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $17.63.

Amicus Therapeutics Price Performance

Shares of FOLD opened at $9.66 on Tuesday. The company has a debt-to-equity ratio of 2.18, a current ratio of 3.15 and a quick ratio of 2.42. The company has a market cap of $2.89 billion, a P/E ratio of -28.41 and a beta of 0.68. Amicus Therapeutics, Inc. has a 12 month low of $9.02 and a 12 month high of $14.57. The stock has a fifty day moving average price of $10.96 and a 200 day moving average price of $10.61.

Insider Transactions at Amicus Therapeutics

In related news, CEO Bradley L. Campbell sold 7,901 shares of Amicus Therapeutics stock in a transaction dated Wednesday, November 6th. The shares were sold at an average price of $12.50, for a total value of $98,762.50. Following the sale, the chief executive officer now directly owns 886,654 shares in the company, valued at $11,083,175. This trade represents a 0.88 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Over the last quarter, insiders sold 30,401 shares of company stock worth $352,038. Insiders own 2.20% of the company’s stock.

Amicus Therapeutics Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.